Biosimilars work as well as the original biologics. Uptake still lags.

A biosimilar is a near-copy of an expensive biologic drug, and by the standard the FDA uses to approve one, it has "no clinically meaningful differences from the reference product" — meaning a patient should expect the same safety and effectiveness [s1]. The best switching trial available backs that up. The reason biosimilars have not delivered the savings generics did is not that they work less well; it is that the market for them has been slow and contested.

What a biosimilar is, and why it can't be identical

Most drugs are small chemical molecules that a generic maker can reproduce exactly. Biologics are different: they are large, complex proteins grown in living cells — the drugs behind rheumatoid arthritis, Crohn's disease, psoriasis and many cancers — and no manufacturer, including the original maker from batch to batch, can produce a protein that is molecularly identical every time. So the law does not ask a biosimilar to be identical. It asks it to be "highly similar" to an already-approved biologic, the reference product, with no clinically meaningful differences in safety or effectiveness [s1].

That is a demanding bar, established through extensive analytical, laboratory and clinical comparison rather than by repeating the original drug's full trial programme. The FDA's plain-language summary to patients is direct: you can expect the same safety and effectiveness from the biosimilar over the course of treatment as from the reference product [s1].

The switching evidence

The sharpest test of a biosimilar is not whether a new patient can start on it but whether a patient stable on the original can be switched without losing control of their disease. The NOR-SWITCH trial, published in The Lancet in 2017, was built to answer exactly that. It was a 52-week, randomised, double-blind trial of 482 patients doing well on the originator biologic infliximab, who were then either kept on it or switched to the biosimilar CT-P13 [s2].

Disease worsening occurred in 26% of patients kept on the original and 30% of those switched to the biosimilar — a difference of −4.4 percentage points, with a 95% confidence interval running from −12.7 to 3.9, comfortably inside the trial's prespecified 15% non-inferiority margin [s2]. Serious adverse events were similar: 10% on the original versus 9% on the biosimilar [s2]. The trial covered a mix of conditions, including Crohn's disease, ulcerative colitis, spondyloarthritis, rheumatoid arthritis, psoriatic arthritis and plaque psoriasis [s2]. Its conclusion was that switching was not inferior to staying on the originator.

One trial is one trial, and NOR-SWITCH studied a single biosimilar of a single biologic. But it is a large, well-designed, independent study — funded by the Norwegian government, not a manufacturer — and it directly tested the scenario patients and doctors worry about most.

"Interchangeable" is a regulatory label, not a quality grade

A source of confusion worth clearing up: some biosimilars carry an additional FDA designation called "interchangeable." That does not mean they are better or more similar than other biosimilars. It is a regulatory status meaning the product met extra requirements allowing a pharmacist to substitute it for the original without contacting the prescriber — "pharmacy-level substitution," which is then subject to state law, much as generics are swapped for brands [s1]. A biosimilar without the interchangeable label is held to the same core standard of no clinically meaningful difference; it simply cannot be auto-substituted at the counter.

The gap is in the market, not the medicine

If biosimilars work and cost less, why have they not repeated the generic drug success story? The savings are real but modest so far. The average biosimilar launches at a price more than 50% below the brand biologic's price, and biosimilar use had saved nearly $24 billion since 2015 as of the 2023 accounting — meaningful, but a fraction of what full competition would yield [s3]. The reason the ceiling is low is structural: biologics make up less than 3% of US prescriptions but more than half of all drug spending, so the stakes are enormous and the incumbents fight hard to protect them [s3].

Uptake has been uneven — some biosimilar markets have taken off while others have barely moved — and industry analysts attribute the lag to a tangle of patent litigation that delays launches, rebate arrangements that reward insurers and middlemen for keeping the higher-priced original on the formulary, and physician and patient unfamiliarity [s3]. None of those are safety concerns. They are frictions in how the drugs get paid for and prescribed.

What the evidence supports

The claim that biosimilars are inferior or riskier than the biologics they copy is not supported by the approval standard or by the switching evidence [s1] [s2]. The claim that they have delivered generic-scale savings is also not supported — they have not, and the reasons are commercial and legal rather than clinical [s3]. The accurate statement sits between the two: biosimilars are held to a bar of no clinically meaningful difference, the head-to-head trial evidence backs that up, and the money they could save is being left on the table by a market that has been slow to let them compete.